Japan's Megakaryon To Develop Mass-Producible Blood Drug
This article was originally published in PharmAsia News
Megakaryon, a start-up Japanese bioventure, said it seeks to develop hemostatic drugs for the local and U.S. markets as early as 2018 to bypass sometimes risky donated blood products.
You may also be interested in...
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.
The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.